Nordic Issuing

Ongoing case

Clinical Laserthermia Systems AB

Back to all cases

Clinical Laserthermia Systems AB

14 Feb - 28 Feb 2023Warrant exercise TO 5

Clinical Laserthermia Systems is active in medical technology. The companys vision is to develop and streamline the treatment of solid cancer tumors, where the company is a seller of sterile patient kits. The products are used in various cancer treatments such as the treatment of malignant melanoma, as well as cancer of the lungs, liver and pancreas. The company was founded in 2006 and is headquartered in Lund, Sweden

At CLS, they aim at getting doctors as close as possible to the clinical problem and provide the means needed for solving it – without causing another. They do this by providing precise tools for image-guided laser-mediated thermal ablations.

Thermal ablation is used for treatment and removal of diseased or abnormal soft tissues, such as malignant tumors (cancer) or epileptogenic foci. The procedure is minimally invasive and can therefore be offered also to patients that are considered inoperable in view of traditional open surgery.

Read more on the company's website

The offer in summary

Subscription period: 14 February - 28 February 2023

Price per share: SEK 0.46

Trading with warrants: Until 24 February 2023

Terms: One (1) warrant of serie TO 5 B gives you the right to subscribe for one (1) new B-share.

Payment day: 28 February 2023

Market Place: First North Stockholm

Financial Adviser: Sedermera Corporate Finance

Subscribe directly via your bank


  Subscription form Teaser


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.